OverviewSuggest Edit

For the millions of men currently living with prostate cancer, and the thousands more who are diagnosed with it every year, current treatment options often mean having to make difficult choices based on potential side effects that can significantly impact quality of life. Our mission is to profoundly change the standard of care by creating a tomorrow where clinicians can confidently ablate cancerous prostate tissue with precision, while actively protecting critical anatomy from potential side effects; a tomorrow where patients have access to a safe, fast and effective treatment option, so they can quickly return to their daily lives.

Established in 2008, Profound Medical is commercializing a novel technology, TULSA-PRO™, which combines real-time Magnetic Resonance Imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control that is designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential side effects. TULSA-PRO™ is CE Marked and Profound is sponsoring a multicenter, prospective FDA-registered clinical trial, TACT, which is designed to further demonstrate the safety and effectiveness of this innovative technology.

TypePublic
Founded2008
HQMississauga, CA
Websiteprofoundmedical.com
Employee Ratings4.2

Latest Updates

Employees (est.) (Dec 2019)75(+18%)
Share Price (Oct 2020)C$22.4
Cybersecurity ratingCMore

Key People/Management at Profound Medical

Arun Menawat

Arun Menawat

Chairman, Chief Executive Officer
Aaron Davidson

Aaron Davidson

Chief Financial Officer & SVP Corporate Development
Rashed Dewan

Rashed Dewan

VP, Finance
Goldy Singh

Goldy Singh

VP, Regulatory Affairs & Product Management
Mathieu Burtnyk

Mathieu Burtnyk

VP, Clinical Affairs
Arthur L. Rosenhal

Arthur L. Rosenhal

Director
Show more

Profound Medical Office Locations

Profound Medical has offices in Mississauga, Vantaa and Hamburg
Mississauga, CA (HQ)
6 2400 Skymark Ave
Vantaa, FI
Äyritie 4
Hamburg, DE
9 Kehrwieder
Show all (3)

Profound Medical Financials and Metrics

Profound Medical Revenue

Market capitalization (15-Oct-2020)

434.3m

Closing stock price (15-Oct-2020)

22.4
Profound Medical's current market capitalization is C$434.3 m.
Show all financial metrics

Profound Medical Cybersecurity Score

Cybersecurity ratingPremium dataset

C

78/100

SecurityScorecard logo

Profound Medical Online and Social Media Presence

Embed Graph

Profound Medical News and Updates

Profound Medical Announces Fourth Quarter and Full Year 2019 Financial Results

TORONTO, March 03, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and clo…

Profound Medical Announces Pricing of Offering of Common Shares

TORONTO, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the pricing of an underwritten public offering (the “Offering”) of 2,950,000 common shares of the Company (the “Common Shares”), at a price of US$11.65 per…

Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Revenues & Provides TULSA-PRO® U.S. Commercialization Update

TORONTO, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and clos…

Profound Medical Announces Pricing of Offerings

NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES

Profound Medical to Present at the Canaccord Genuity 39th Annual Growth Conference

TORONTO, July 31, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedb…

Profound Medical to Release Second Quarter 2019 Financial Results on August 14 – Conference Call to Follow

TORONTO, July 30, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedb…
Show more

Profound Medical Blogs

Protected: TULSA-PRO USER MEETING

There is no excerpt because this is a protected post.

Message from our CEO

Protected: AUA2020: TULSA Dinner

There is no excerpt because this is a protected post.
Show more

Profound Medical Frequently Asked Questions

  • When was Profound Medical founded?

    Profound Medical was founded in 2008.

  • Who are Profound Medical key executives?

    Profound Medical's key executives are Arun Menawat, Aaron Davidson and Rashed Dewan.

  • How many employees does Profound Medical have?

    Profound Medical has 75 employees.

  • Who are Profound Medical competitors?

    Competitors of Profound Medical include Butterfly Network, Kallo and InspireMD.

  • Where is Profound Medical headquarters?

    Profound Medical headquarters is located at 6 2400 Skymark Ave, Mississauga.

  • Where are Profound Medical offices?

    Profound Medical has offices in Mississauga, Vantaa and Hamburg.

  • How many offices does Profound Medical have?

    Profound Medical has 3 offices.